Pioglitazone

CAS No. 111025-46-8

Pioglitazone( U-72107 )

Catalog No. M10411 CAS No. 111025-46-8

Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 32 In Stock
10MG 43 In Stock
25MG 57 In Stock
50MG 88 In Stock
100MG 129 In Stock
500MG 317 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pioglitazone
  • Note
    Research use only, not for human use.
  • Brief Description
    Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
  • Description
    Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.(In Vitro):Pioglitazone (0.5 or 1 μM, 5 days) can completely prevent AGEs (advanced glycation end-products)-induced β-cell necrosis and the increase of caspase-3 thereby avoiding the impaired viability caused by AGEs in pancreatic beta cell line HIT-T15.Pioglitazone (1 μM, 1 h) can stimulate insulin secretion induced by low glucose concentration and attenuate the GSSG/GSH ratio in cells cultured with AGEs.(In Vivo):Pioglitazone (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle.Pioglitazone (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia.
  • In Vitro
    ——
  • In Vivo
    Animal Model:ob/ob and adipo-/- ob/ob mice with a C57Bl/6 backgroundDosage:10 or 30 mg/kgAdministration:Oral gavage; once daily; 14 daysResult:Showed no changes of serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- ob/ob C57BL/6 mice at 10 mg/kg but significantly reduced to a similar degree at 30 mg/kg.Also showed no changes of expressions of TNFα and resistin in adipose tissues of ob/ob and adipo-/- ob/ob mice at 10 mg/kg but decreased at 30 mg/kg.Animal Model:Male Wistar albino rats Dosage:10 mg/kg Administration:Oral gavage; once daily; 4 weeks Result:Decreased the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB), TGF-β1 gene expression and regulated the expression of MMP-2/TIMP-2 system.
  • Synonyms
    U-72107
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    111025-46-8
  • Formula Weight
    356.44
  • Molecular Formula
    C19H20N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 15 mg/mL (42.08 mM)
  • SMILES
    O=C(C(S1)CC(C=C2)=CC=C2OCCC3=NC=C(CC)C=C3)[N]C1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jaakkola T, et al. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-5
molnova catalog
related products
  • Rosiglitazone

    A potent and selective PPARγ agonist that binds to the PPARγ ligand-binding domain with a Kd of 40 nM.

  • Pioglitazone hydroch...

    Pioglitazone hydrochloride can increase both insulin-stimulated glucose uptake in peripheral tissues and insulin sensitivity in hepatic and adipose tissue.

  • Furegrelate sodium

    Furegelate sodium is a selective thromboxane synthase inhibitor with oral activity.